JP7662534B2 - 脂肪族酸アミド誘導体 - Google Patents

脂肪族酸アミド誘導体 Download PDF

Info

Publication number
JP7662534B2
JP7662534B2 JP2021567520A JP2021567520A JP7662534B2 JP 7662534 B2 JP7662534 B2 JP 7662534B2 JP 2021567520 A JP2021567520 A JP 2021567520A JP 2021567520 A JP2021567520 A JP 2021567520A JP 7662534 B2 JP7662534 B2 JP 7662534B2
Authority
JP
Japan
Prior art keywords
alkyl
compound
pharma
acceptable salt
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021567520A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021132311A5 (https=
JPWO2021132311A1 (https=
Inventor
佑樹 藤井
雅幸 佐久間
佳典 相原
ジェレミー・ベスナルド
アンドリュー・シモン・ベル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd, Sumitomo Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of JPWO2021132311A1 publication Critical patent/JPWO2021132311A1/ja
Publication of JPWO2021132311A5 publication Critical patent/JPWO2021132311A5/ja
Application granted granted Critical
Publication of JP7662534B2 publication Critical patent/JP7662534B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2021567520A 2019-12-24 2020-12-23 脂肪族酸アミド誘導体 Active JP7662534B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019232927 2019-12-24
JP2019232927 2019-12-24
PCT/JP2020/048117 WO2021132311A1 (ja) 2019-12-24 2020-12-23 脂肪族酸アミド誘導体

Publications (3)

Publication Number Publication Date
JPWO2021132311A1 JPWO2021132311A1 (https=) 2021-07-01
JPWO2021132311A5 JPWO2021132311A5 (https=) 2023-12-12
JP7662534B2 true JP7662534B2 (ja) 2025-04-15

Family

ID=76574184

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021567520A Active JP7662534B2 (ja) 2019-12-24 2020-12-23 脂肪族酸アミド誘導体

Country Status (14)

Country Link
US (3) US12503463B2 (https=)
EP (1) EP4082616B1 (https=)
JP (1) JP7662534B2 (https=)
KR (1) KR20220120625A (https=)
CN (1) CN114981264B (https=)
AU (1) AU2020413284A1 (https=)
BR (1) BR112022011844A2 (https=)
CA (1) CA3161806A1 (https=)
ES (1) ES3040677T3 (https=)
HU (1) HUE072877T2 (https=)
MX (1) MX2022007947A (https=)
PL (1) PL4082616T3 (https=)
PT (1) PT4082616T (https=)
WO (1) WO2021132311A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220120625A (ko) * 2019-12-24 2022-08-30 스미토모 파마 가부시키가이샤 지방족 산 아미드 유도체
JP7655885B2 (ja) * 2021-06-30 2025-04-02 住友ファーマ株式会社 脂肪族酸アミド誘導体を含有する医薬組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508101A (ja) 2002-11-08 2006-03-09 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー フェニルアルキルおよびピリジルアルキルピペラジン誘導体
JP2008539268A (ja) 2005-04-26 2008-11-13 ハイプニオン・インコーポレイテッド ベンズイソオキサゾールピペラジン化合物およびその使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880930A (en) 1987-11-30 1989-11-14 New James S Psychotropic acyclic amide derivatives
EP0732332B1 (en) 1995-03-17 2001-12-19 Aventis Pharmaceuticals Inc. Substituted benzothienylpiperazines, their use as medicaments, and processes for their preparation
US5880121A (en) * 1996-01-05 1999-03-09 Hoechst Marion Roussel Inc. 4,5-dihydronaphth (1,2-c) isoxazoles and derivatives thereof
JP4497815B2 (ja) 2001-02-16 2010-07-07 アベンティス・ファーマスーティカルズ・インコーポレイテツド 新規な複素環式アミド誘導体およびドーパミンｄ３受容体リガンドとしてのその使用
FR2827287B1 (fr) * 2001-07-13 2003-10-31 Servier Lab Nouveaux derives de benzene sulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PL392436A1 (pl) 2010-09-17 2012-03-26 Adamed Spółka Z Ograniczoną Odpowiedzialnością Pochodne arylosulfonamidów do leczenia chorób odśrodkowego układu nerwowego
WO2014079155A1 (zh) * 2012-11-26 2014-05-30 辽宁贝雷生物制药有限公司 苯并五元氮杂环基哌嗪或哌啶衍生物的用途
KR20220120625A (ko) * 2019-12-24 2022-08-30 스미토모 파마 가부시키가이샤 지방족 산 아미드 유도체

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508101A (ja) 2002-11-08 2006-03-09 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー フェニルアルキルおよびピリジルアルキルピペラジン誘導体
JP2008539268A (ja) 2005-04-26 2008-11-13 ハイプニオン・インコーポレイテッド ベンズイソオキサゾールピペラジン化合物およびその使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NORMAN, Mark H. et al.，Synthesis and Evaluation of Heterocyclic Carboxamides as Potential Antipsychotic Agents，J. Med. Chem.，1996年，Vol.39，pp.4692-4703
Registry(STN)[online]，2019年06月04日，p.1，CAS登録番号 2323720-22-3、2323323-46-0

Also Published As

Publication number Publication date
US12503463B2 (en) 2025-12-23
TW202136235A (zh) 2021-10-01
KR20220120625A (ko) 2022-08-30
CA3161806A1 (en) 2021-07-01
EP4082616A1 (en) 2022-11-02
US20220073506A1 (en) 2022-03-10
US20260078115A1 (en) 2026-03-19
JPWO2021132311A1 (https=) 2021-07-01
BR112022011844A2 (pt) 2022-08-30
WO2021132311A1 (ja) 2021-07-01
EP4082616B1 (en) 2025-09-03
US11339151B2 (en) 2022-05-24
CN114981264A (zh) 2022-08-30
PL4082616T3 (pl) 2025-12-15
MX2022007947A (es) 2022-07-27
EP4082616A4 (en) 2024-01-03
AU2020413284A1 (en) 2022-08-18
US20220213079A1 (en) 2022-07-07
PT4082616T (pt) 2025-12-02
HUE072877T2 (hu) 2025-12-28
CN114981264B (zh) 2024-07-26
ES3040677T3 (en) 2025-11-04

Similar Documents

Publication Publication Date Title
CA2957046C (en) Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
TW202134229A (zh) 環烷基尿素衍生物
CN103917534B (zh) 作为h3受体抑制剂的包含哌啶和哌嗪环的氨基甲酸酯/脲衍生物
US20260078115A1 (en) Aliphatic acid amide derivative
CA2878006C (en) Carbamate/urea derivatives
AU2020408107B2 (en) Compounds active towards nuclear receptors
AU2017207991A1 (en) Pyridazine derivatives as EAAT2 activators
CN117561238A (zh) 苯基脲衍生物
CA3103932A1 (en) Pyridinyl pyrazoles as modulators of roryt
JP7097342B2 (ja) ２，６－ジ置換ピリジン誘導体
JP7655885B2 (ja) 脂肪族酸アミド誘導体を含有する医薬組成物
TWI917344B (zh) 脂肪族酸醯胺衍生物
WO2017018475A1 (ja) 新規リンカー部位を持つ縮合ピラゾール誘導体およびその医薬用途
CA3199269A1 (en) Isoxazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
HK40079616B (en) Aliphatic acid amide derivative
HK40079616A (en) Aliphatic acid amide derivative
EA046822B1 (ru) Производное амида алифатической кислоты
BR112017005241B1 (pt) Composto, composição farmacêutica, e, uso de um composto
JP7382188B2 (ja) ２，６－ジ置換ピリジン誘導体からなる医薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241223

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250325

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250403

R150 Certificate of patent or registration of utility model

Ref document number: 7662534

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150